New England Research & Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.23M | Sell |
24,774
-736
| -3% | -$158K | 2.43% | 7 |
|
|
2026
Q1 | $5.55M | Buy |
25,510
+3,929
| +18% | +$872K | 2.34% | 7 |
|
|
2025
Q4 | $4.93M | Buy |
21,581
+1,780
| +9% | +$405K | 2.16% | 8 |
|
|
2025
Q3 | $4.58M | Sell |
19,801
-640
| -3% | -$130K | 2.11% | 9 |
|
|
2025
Q2 | $3.79M | Buy |
20,441
+1,335
| +7% | +$248K | 1.8% | 12 |
|
|
2025
Q1 | $4M | Sell |
19,106
-2,266
| -11% | -$441K | 2.03% | 11 |
|
|
2024
Q4 | $3.8M | Buy |
21,372
+8,280
| +63% | +$1.52M | 1.93% | 11 |
|
|
2024
Q3 | $2.58M | Buy |
13,092
+1,616
| +14% | +$302K | 1.21% | 23 |
|
|
2024
Q2 | $1.97M | Buy |
11,476
+6,408
| +126% | +$1.06M | 0.95% | 32 |
|
|
2024
Q1 | $923K | Buy |
5,068
+41
| +0.8% | +$7.07K | 0.45% | 77 |
|
|
2023
Q4 | $779K | Sell |
5,027
-573
| -10% | -$83.5K | 0.41% | 84 |
|
|
2023
Q3 | $835K | Sell |
5,600
-333
| -6% | -$48.9K | 0.48% | 74 |
|
|
2023
Q2 | $799K | Sell |
5,933
-22
| -0.4% | -$3.23K | 0.46% | 74 |
|
|
2023
Q1 | $949K | Sell |
5,955
-100
| -2% | -$15.3K | 0.56% | 69 |
|
|
2022
Q4 | $979K | Sell |
6,055
-3,075
| -34% | -$471K | 0.56% | 68 |
|
|
2022
Q3 | $1.23M | Buy |
9,130
+3,100
| +51% | +$445K | 0.77% | 41 |
|
|
2022
Q2 | $924K | Hold |
6,030
| – | – | 0.54% | 66 |
|
|
2022
Q1 | $978K | Sell |
6,030
-9,628
| -61% | -$1.4M | 0.51% | 68 |
|
|
2021
Q4 | $2.12M | Hold |
15,658
| – | – | 1.03% | 26 |
|
|
2021
Q3 | $1.69M | Sell |
15,658
-75
| -0.5% | -$8.57K | 0.88% | 36 |
|
|
2021
Q2 | $1.77M | Sell |
15,733
-50
| -0.3% | -$5.63K | 0.92% | 32 |
|
|
2021
Q1 | $1.71M | Buy |
15,783
+63
| +0.4% | +$6.74K | 0.94% | 34 |
|
|
2020
Q4 | $1.68M | Buy |
15,720
+1,100
| +8% | +$106K | 1.04% | 29 |
|
|
2020
Q3 | $1.28M | Sell |
14,620
-85
| -0.6% | -$8K | 0.93% | 32 |
|
|
2020
Q2 | $1.44M | Buy |
14,705
+4,750
| +48% | +$418K | 1.03% | 26 |
|
|
2020
Q1 | $758K | Sell |
9,955
-425
| -4% | -$36.2K | 0.65% | 56 |
|
|
2019
Q4 | $919K | Sell |
10,380
-1,450
| -12% | -$120K | 0.62% | 61 |
|
|
2019
Q3 | $896K | Buy |
11,830
+4,750
| +67% | +$326K | 0.65% | 52 |
|
|
2019
Q2 | $515K | Sell |
7,080
-1,079
| -13% | -$84.8K | 0.35% | 99 |
|
|
2019
Q1 | $658K | Buy |
8,159
+300
| +4% | +$24.5K | 0.44% | 79 |
|
|
2018
Q4 | $725K | Sell |
7,859
-5,674
| -42% | -$499K | 0.57% | 63 |
|
|
2018
Q3 | $1.28M | Sell |
13,533
-2,650
| -16% | -$251K | 0.83% | 42 |
|
|
2018
Q2 | $1.5M | Buy |
16,183
+1,850
| +13% | +$181K | 0.99% | 28 |
|
|
2018
Q1 | $1.36M | Buy |
14,333
+9,800
| +216% | +$1.08M | 0.91% | 37 |
|
|
2017
Q4 | $438K | Sell |
4,533
-4,775
| -51% | -$450K | 0.31% | 100 |
|
|
2017
Q3 | $827K | Buy |
9,308
+4,700
| +102% | +$358K | 0.61% | 63 |
|
|
2017
Q2 | $334K | Hold |
4,608
| – | – | 0.25% | 121 |
|
|
2017
Q1 | $300K | Sell |
4,608
-4,150
| -47% | -$261K | 0.23% | 132 |
|
|
2016
Q4 | $548K | Buy |
8,758
+4,950
| +130% | +$302K | 0.43% | 76 |
|
|
2016
Q3 | $240K | Sell |
3,808
-11,700
| -75% | -$757K | 0.2% | 145 |
|
|
2016
Q2 | $960K | Sell |
15,508
-3,100
| -17% | -$189K | 0.83% | 38 |
|
|
2016
Q1 | $1.06M | Buy |
18,608
+1,950
| +12% | +$109K | 0.9% | 34 |
|
|
2015
Q4 | $987K | Buy |
16,658
+7,550
| +83% | +$435K | 0.85% | 32 |
|
|
2015
Q3 | $496K | Buy |
9,108
+4,300
| +89% | +$280K | 0.47% | 77 |
|
|
2015
Q2 | $323K | Sell |
4,808
-11,099
| -70% | -$725K | 0.26% | 126 |
|
|
2015
Q1 | $931K | Buy |
15,907
+7,499
| +89% | +$453K | 0.8% | 40 |
|
|
2014
Q4 | $550K | Sell |
8,408
-200
| -2% | -$12.6K | 0.47% | 90 |
|
|
2014
Q3 | $497K | Sell |
8,608
-550
| -6% | -$30.5K | 0.43% | 97 |
|
|
2014
Q2 | $517K | Sell |
9,158
-5,400
| -37% | -$283K | 0.46% | 90 |
|
|
2014
Q1 | $748K | Buy |
14,558
+4,700
| +48% | +$238K | 0.69% | 59 |
|
|
2013
Q4 | $521K | Buy |
+9,858
| New | +$485K | 0.5% | 80 |
|
Other funds holding ABBV
New England Research & Management's ABBV Position: Q2 2026 in Review
New England Research & Management reduced its AbbVie (ABBV) stake by 2.9% in Q2 2026, selling an estimated $158K and leaving 24,774 shares worth $6.23M. The position accounts for 2.43% of the portfolio, ranked #7.
New England Research & Management first reported a position in ABBV in Q4 2013 and has held it in 51 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- New England Research & Management held 24,774 shares of AbbVie worth $6.23M as of Q2 2026.
- New England Research & Management sold 736 AbbVie shares in Q2 2026, an estimated $158K.
- AbbVie made up 2.43% of New England Research & Management's portfolio in Q2 2026, its #7 holding.
- New England Research & Management first reported a position in AbbVie in Q4 2013 and has held it in 51 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on New England Research & Management's 13F filing for Q2 2026, filed 9 Jul 2026.